News Center

Discover all of the trending news of the Ipsen Group

10 results


Web conference on Merrimack announcement

Conference call & web conference: Date: 9 January, 2017 Time: 2:30pm CET/ 8:30am EST  …


Ipsen launches a new dedicated website for patients living with neuroendocrine tumours: built with patients for patients*

An uncommon and relatively unknown disease Neuroendocrine tumors (NETs) are most commonly found in the…


Latest news on the cabozantinib program

During this conference, Exelixis and Ipsen management and invited guest speakers have reviewed…


FDA Approval of Dysport® for injection for the treatment of Lower Limb Spasticity in children aged two and older

A condition in which there is an abnormal increase in muscle tone or stiffness Spasticity…


Positive CHMP opinion for CabometyxTM (cabozantinib)

Accelerated review procedure The positive CHMP opinion was adopted following an accelerated review procedure reserved…


Aepodia integrates Ipsen’s R&D Campus in Paris-Saclay biotechnology hub

[caption id="attachment_2410" align="alignleft" width="300"] R&D center in Les Ulis[/caption] Aepodia is a solution provider…

Group People

Celebration of Ipsen Canadian Headquarters Grand Opening in Mississauga, Ontario

From left to right: Lyndal Walker, Marc de Garidel, Hon. Dipika Damerla, Cynthia Schwalm, Marc Trouyet. Ipsen will…

Group People

Opening of a new manufacturing facility in Russia

The opening ceremony was held with participation of Olga Kazanskaya, Vice-Governor of Saint Petersburg,…


A new R&D center in Cambridge (USA)

Ipsen’s state-of-the-art R&D center is located in Cambridge, one of the world’s most vibrant biomedical…

© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved. - 2020